CasImg
锌原卟啉
产品纠错
CAS号:15442-64-5 | 英文名称:PROTOPORPHYRINATO ZINC
分子式 C34H31N4O4Zn-
分子量 625
EINECS号 239-455-7
MDL MFCD00011612
Smiles
InChIKey
乙二醇化学百科
基本信息
中文名称 锌原卟啉
英文名称 PROTOPORPHYRINATO ZINC
CAS号 15442-64-5
分子式 C34H31N4O4Zn-
分子量 625.03
EINECS号 239-455-7
物化性质
溶解度 DMSO:50 mg/mL(79.87 mM;需要超声波)H2O:< 0.1 mg/mL(不溶)
形态 结晶
颜色 暗红色至紫色
水溶解性 Insoluble in water. Soluble in ethanol, and DMSO, pyridine, or dimethyl formamide.
稳定性 吸湿性
安全信息
WGK Germany 3
RTECS号 ZG9210300
TSCA Yes
生产及用途
Zinc Protoporphyrin (Zn(II)-protoporphyrin IX) 是一种具有口服活性的,竞争性的血红素加氧酶-1 (HO-1) 抑制剂,显着减弱间苯三酚 (PG) 对 H2O2 的保护作用。Zinc Protoporphyrin 可用作个体孕妇和儿童缺铁的筛查标志物,也用于评估人群铁状态与血红蛋白浓度的组合。Zinc Protoporphyrin 具有抗癌活性。

Human Endogenous Metabolite

Zinc Protoporphyrin (Zn(II)-protoporphyrin IX; 5 μM; 72 hours) causes the fraction of late apoptotic and necrotic cells increasing from 10.9% in controls to 30.4% after 72 h.
Zinc Protoporphyrin (1.25-40 μM; 48 or 72 hours) exerts cystostatic/cytotoxic effects against tumor cells.
Zinc Protoporphyrin (2.5, 5 μM; 48 or 72 hours) results in dose- and time-dependent reduction of cells in G1 phase of the cell cycle.
Zinc Protoporphyrin (1.25-40 μM; 48 hours) leads to accumulation of cleaved (active) caspase-3.

Apoptosis Analysis

Cell Line: C-26 cells
Concentration: 5 μM
Incubation Time: 72 hours
Result: The fraction of late apoptotic and necrotic cells increased from 10.9% in controls to 30.4% after 72 h.

Cell Cytotoxicity Assay

Cell Line: C-26 and MDA-MB231 cells
Concentration: 1.25, 2.5, 5, 10, 20, 40 μM
Incubation Time: 48 or 72 hours
Result: Exerted cystostatic/cytotoxic effects against tumor cells.

Cell Cycle Analysis

Cell Line: C-26 cells
Concentration: 2.5, 5 μM
Incubation Time: 48 or 72 hours
Result: Resulted in dose- and time-dependent reduction of cells in G1 phase of the cell cycle.

Western Blot Analysis

Cell Line: C-26 cells
Concentration: 1.25, 2.5, 5, 10, 20, 40 μM
Incubation Time: 48 hours
Result: Leaded to accumulation of cleaved (active) caspase-3.

Zinc Protoporphyrin (12.5, 25, 50 mg/kg for i.p.; 12.5, 50 mg/kg for p.o.; from day 7 to 19) exerts dose-dependent antitumor effects manifested by the retardation of tumor growth.

Animal Model: BALB/c mice inoculated with C-26 cells
Dosage: 12.5, 25, 50 mg/kg for i.p.; 12.5, 50 mg/kg for p.o.
Administration: IP or PO; from day 7 to 19
Result: Exerted dose-dependent antitumor effects manifested by the retardation of tumor growth.
上下游产品
上游产品共计:0个
下游产品共计:0个
产品供应商

首页 |  CAS目录 |  产品目录 |  企业会员 |  关于我们 |  法律声明 |  注册协议

Copyright © 冀ICP备2024096099号